Top Markets
#1 Helium Helium +57.25%
#2 Seeker Seeker +36.80%
#3 Pons Pons +26.62%
#4 TENDIES TENDIES +24.40%
#5 Zylo Ecosystem Zylo Ecosystem +24.40%
#6 UnifAI Network UnifAI Network +21.04%
#7 Bounce Bounce +20.57%
#8 Zora Zora +14.78%
#9 DAPPOS DAPPOS +13.42%
#10 ZKsync ZKsync +12.91%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classificação em ações #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Preço da ação
$9.50
Última sincronização: 2025-01-08
Valor de mercado
$819.52M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Poseida Therapeutics, Inc. (PSTX)

Categoria

Healthcare
Margem Operacional de Poseida Therapeutics, Inc. (PSTX)
Margem Operacional em August 2026 TTM: -200.15%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Poseida Therapeutics, Inc., a margem operacional atual (TTM) é -200.15%. No final de 2022, a margem operacional era -45.98%.
Histórico da Margem Operacional da Poseida Therapeutics, Inc. de 2016 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
2026 (TTM) -200.15% 0.00%
2023 -200.15% 335.30%
2022 -45.98% -89.84%
2021 -452.69% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% -100.00%
2017 -658.89% 1,081.23%
2016 -55.78% 0.00%
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.19%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.14%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.13%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.26%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.